CLINICAL TRIALS PROFILE FOR ORENCIA
✉ Email this page to a colleague
All Clinical Trials for ORENCIA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00035529 ↗ | A Study to Evaluate the Preliminary Efficacy Pharmacokinetics and Immunogenicity of BMS-188667 Administered to Subjects With Relapsing-remitting Multiple Sclerosis | Terminated | Bristol-Myers Squibb | Phase 2 | 2001-11-01 | The purpose of this study is to determine whether BMS-188667 will decrease multiple sclerosis disease activity on MRI examinations, as well as decrease the rate of clinical MS exacerbations, compared to placebo |
| NCT00048581 ↗ | Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past. | Completed | Bristol-Myers Squibb | Phase 3 | 2002-12-01 | The purpose of this clinical research study is to determine whether abatacept treatment on a background of Disease Modifying Antirheumatic Drugs (DMARDs) will relieve the symptoms of rheumatoid arthritis (RA) in participants who are currently receiving anti-tumor necrosis factor (TNF) therapy for at least 3 months and are not responding or have taken anti-TNF therapy in the last 3 months and did not respond. The safety of treatment with abatacept will also be evaluated. This study also has a 4.5-year long-term extension beginning 6 months after the start of the study. |
| NCT00048932 ↗ | A Phase III Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis | Completed | Bristol-Myers Squibb | Phase 3 | 2002-12-01 | The purpose of this clinical research study is to learn if abatacept is safe when co-administered with other approved rheumatoid arthritis medications. |
| NCT00095147 ↗ | Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis | Completed | Bristol-Myers Squibb | Phase 3 | 2005-02-01 | The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo. |
| NCT00095173 ↗ | BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis | Completed | Bristol-Myers Squibb | Phase 3 | 2003-12-01 | The primary purpose of the clinical research study is to assess the safety of treating children and juvenile subjects with BMS-188667 (Abatacept). In addition, the study will assess the effectiveness of BMS-188667 in reducing disease activity of Juvenile Rheumatoid Arthritis (JRA) or Juvenile Idiopathic Arthritis (JIA) as measured by the time to occurrence of disease flare. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ORENCIA
Condition Name
Clinical Trial Locations for ORENCIA
Trials by Country
Clinical Trial Progress for ORENCIA
Clinical Trial Phase
Clinical Trial Sponsors for ORENCIA
Sponsor Name
